Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Review links iron-dependent cell death to pathogenesis of Friedreich's Ataxia

30

Jun 2026

Review links iron-dependent cell death to pathogenesis of Friedreich's Ataxia

Published in the open-access journal Ferroptosis and Oxidative Stress, the review by Giovanni Cravin and Giorgio Cozza from the University of Padua examines the growing evidence linking ferroptosis to the pathogenesis of Friedreich's Ataxia (FRDA), a rare inherited neurodegenerative disease characterized by progressive neurological decline, cardiomyopathy, and premature mortality.

Nerve stimulation methods provide safe relief for oropharyngeal dysphagia

30

Jun 2026

Nerve stimulation methods provide safe relief for oropharyngeal dysphagia

Dysphagia, a severe comorbidity of many neurological diseases, often lacks targeted therapies. This critical review assessed the clinical effectiveness and safety of electrical stimulation of cranial nerves for treating dysphagia, including implantable (direct nerve stimulation), minimally invasive (pharyngeal electrical stimulation, PES), and non‑invasive (transcutaneous) approaches.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.